AzurRx BioPharma Inc (NASDAQ:AZRX) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Brokerages have set a 1-year consensus price target of $8.50 for the company and are anticipating that the company will post ($0.24) earnings per share for the current quarter, according to Zacks. Zacks has also assigned AzurRx BioPharma an industry rank of 160 out of 255 based on the ratings given to its competitors.
Several research analysts have recently weighed in on AZRX shares. HC Wainwright set a $6.00 price target on shares of AzurRx BioPharma and gave the company a “buy” rating in a report on Friday, May 25th. ValuEngine upgraded shares of AzurRx BioPharma from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.
AzurRx BioPharma stock opened at $3.11 on Wednesday. AzurRx BioPharma has a twelve month low of $2.25 and a twelve month high of $5.25.
AzurRx BioPharma (NASDAQ:AZRX) last released its quarterly earnings results on Monday, May 14th. The company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.11). equities research analysts expect that AzurRx BioPharma will post -0.86 EPS for the current fiscal year.
A hedge fund recently raised its stake in AzurRx BioPharma stock. Parsons Capital Management Inc. RI lifted its holdings in AzurRx BioPharma Inc (NASDAQ:AZRX) by 20.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 329,515 shares of the company’s stock after purchasing an additional 55,540 shares during the quarter. Parsons Capital Management Inc. RI owned 1.97% of AzurRx BioPharma worth $1,035,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 5.33% of the company’s stock.
About AzurRx BioPharma
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.